Relacatib

Drug Profile

Relacatib

Alternative Names: 462795; GSK-462795; SB-462795

Latest Information Update: 30 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline; Human Genome Sciences
  • Class Azepines; Osteoporosis therapies; Sulfones
  • Mechanism of Action Cathepsin K inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer metastases; Osteoarthritis; Postmenopausal osteoporosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 10 Jan 2006 Phase-II clinical trials in Cancer metastases in USA (PO)
  • 15 Dec 2005 Phase-I clinical trials in Cancer metastases in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top